Sesen's PhI­II blad­der can­cer da­ta send stock south as in­vestors fret over safe­ty

Fol­low­ing a brand­ing makeover just last week, Sesen Bio (which used to go by Eleven Bio­ther­a­peu­tics) has pub­lished three-month da­ta for its blad­der can­cer drug Vicini­um. The re­sults have some in­vestors cau­tious, as the com­pa­ny’s stock — trad­ing un­der the fresh­ly mint­ed tick­er sym­bol $SESN — is down 23% since the an­nounce­ment.

Stephen Hurly

Sesen was lit­tle more than a shell with a bank ac­count a cou­ple years ago af­ter its lead drug failed twice and it com­plet­ed a deal to li­cense out its re­main­ing pro­gram to Roche. But then the en­ti­ty ac­quired Toron­to-based Viven­tia, snag­ging its now lead drug can­di­date Vicini­um, a next-gen an­ti­body-drug con­ju­gate to treat high-grade non-mus­cle in­va­sive blad­der can­cer.

The new Vicini­um da­ta came from an on­go­ing Phase III tri­al called Vista, which en­rolled 133 pa­tients with high-grade NMIBC. These pa­tients had pre­vi­ous­ly been on BCG im­munother­a­py, a stan­dard treat­ment that doesn’t al­ways de­liv­er, said Ri­an Dick­stein, an in­ves­ti­ga­tor in the tri­al.

“For those pa­tients who re­lapse or who don’t re­spond at all, the stan­dard al­ter­na­tive is rad­i­cal cys­tec­to­my,” Dick­stein said in a state­ment. “In a cys­tec­to­my, the blad­der is re­moved along with sur­round­ing lymph nodes and oth­er or­gans that con­tain can­cer.”

Ri­an Dick­stein

Vicini­um is a hope­ful al­ter­na­tive to los­ing the blad­der. Vicini­um was de­vel­oped us­ing the com­pa­ny’s pro­pri­etary tar­get­ed pro­tein ther­a­peu­tics plat­form. The ther­a­py is com­prised of a re­com­bi­nant fu­sion pro­tein that tar­gets ep­ithe­lial cell ad­he­sion mol­e­cule (Ep­CAM) anti­gens on the sur­face of tu­mor cells to de­liv­er a po­tent pro­tein pay­load, Pseudomonas Ex­o­tox­in A.

The com­pa­ny said Ep­CAM is over­ex­pressed in NMIBC but not in healthy blad­der cells, so hom­ing in on it will hope­ful­ly de­crease tox­ic ef­fects in healthy tis­sues.

Sesen’s ef­fi­ca­cy da­ta, which came from 111 pa­tients with can­cer that had not spread from the blad­der in­to mus­cle or oth­er tis­sue, showed that Vicini­um had a com­plete re­sponse rate of 43%.

Four se­ri­ous ad­verse events re­lat­ed to the treat­ment were re­port­ed in the da­ta, in­clud­ing acute kid­ney in­jury or re­nal fail­ure and cholesta­t­ic he­pati­tis, the com­pa­ny said. But 72% of the ad­verse events were classed as grade 1 or 2.

Still, the se­ri­ous ad­verse events ap­pear to have some in­vestors wor­ried, with the com­pa­ny’s stock drop­ping from $3.00 per share to $2.30 by Mon­day’s close.

Stephen Hurly, the com­pa­ny’s pres­i­dent and CEO, said the da­ta are en­cour­ag­ing.

“The Vista tri­al three-month da­ta are en­cour­ag­ing for our com­pa­ny and the pa­tients with high-grade NMIBC who have been un­der­served for many years,” Hurly said. “We have made tremen­dous progress over the last sev­er­al years to get us to where we are to­day, and I am proud of what our team has ac­com­plished. Our new name is a re­flec­tion of the jour­ney we’ve tak­en to get to this point and rep­re­sents our mis­sion of im­prov­ing lives. With 12-month da­ta ex­pect­ed by mid-2019, we are con­tin­u­ing to ad­vance Vicini­um to as­sess its full po­ten­tial in treat­ing this dev­as­tat­ing can­cer.”

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

President Donald Trump (left) and Moncef Slaoui, head of Operation Warp Speed (Alex Brandon, AP Images)

UP­DAT­ED: White House names fi­nal­ists for Op­er­a­tion Warp Speed — with 5 ex­pect­ed names and one no­table omis­sion

A month after word first broke of the Trump Administration’s plan to rapidly accelerate the development and production of a Covid-19 vaccine, the White House has selected the five vaccine candidates they consider most likely to succeed, The New York Times reported.

Most of the names in the plan, known as Operation Warp Speed, will come as little surprise to those who have watched the last four months of vaccine developments: Moderna, which was the first vaccine to reach humans and is now the furthest along of any US effort; J&J, which has not gone into trials but received around $500 million in funding from BARDA earlier this year; the joint AstraZeneca-Oxford venture which was granted $1.2 billion from BARDA two weeks ago; Pfizer, which has been working with the mRNA biotech BioNTech; and Merck, which just entered the race and expects to put their two vaccine candidates into humans later this year.

Leen Kawas, Athira CEO (Athira)

Can a small biotech suc­cess­ful­ly tack­le an Ever­est climb like Alzheimer’s? Athi­ra has $85M and some in­flu­en­tial back­ers ready to give it a shot

There haven’t been a lot of big venture rounds for biotech companies looking to run a Phase II study in Alzheimer’s.

The field has been a disaster over the past decade. Amyloid didn’t pan out as a target — going down in a litany of Phase III failures — and is now making its last stand at Biogen. Tau is a comer, but when you look around and all you see is destruction, the idea of backing a startup trying to find complex cocktails to swing the course of this devilishly complicated memory-wasting disease would daunt the pluckiest investors.

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results from a study testing the drug in lupus patients with associated kidney disease — a post-marketing requirement from the initial FDA approval.

Lupus is a drug developer’s nightmare. In the last six decades, there has been just one FDA approval (Benlysta), with the field resembling a graveyard in recent years with a string of failures including UCB and Biogen’s late-stage flop, as well as defeats in Xencor and Sanofi’s programs. One of the main reasons the success has eluded researchers is because lupus, akin to cancer, is not just one disease — it really is a disease of many diseases, noted Al Roy, executive director of Lupus Clinical Investigators Network, an initiative of New York-based Lupus Research Alliance that claims it is the world’s leading private funder of lupus research, in an interview.

UP­DAT­ED: Es­ti­mat­ing a US price tag of $5K per course, remde­sivir is set to make bil­lions for Gilead, says key an­a­lyst

Data on remdesivir — the first drug shown to benefit Covid-19 patients in a randomized, controlled trial setting — may be murky, but its maker Gilead could reap billions from the sales of the failed Ebola therapy, according to an estimate by a prominent Wall Street analyst. However, the forecast, which is based on a $5,000-per-course US price tag, triggered the ire of one top drug price expert.

FDA de­lays de­ci­sion on No­var­tis’ po­ten­tial block­buster MS drug, wip­ing away pri­or­i­ty re­view

So much for a speedy review.

In February, Novartis announced that an application for their much-touted multiple sclerosis drug ofatumumab had been accepted and, with the drug company cashing in on one of their priority review vouchers, the agency was due for a decision by June.

But with June less than 48 hours old, Novartis announced the agency has extended their review, pushing back the timeline for approval or rejection to September. The Swiss pharma filed the application in December, meaning their new schedule will be nearly in line with the standard 10-month window period had they not used the priority voucher.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.

Gilead bol­sters its case for block­buster hope­ful fil­go­tinib as FDA pon­ders its de­ci­sion

Before remdesivir soaked up the spotlight amid the coronavirus crisis, Gilead’s filgotinib was the star experimental drug tapped to rake in billions competing with other JAK inhibitors made by rivals including AbbVie and Eli Lilly.

Now, long term data on the drug — discovered by Gilead’s partners at Galapagos and posted as part of a virtual medical conference — have solidified the durability and safety of filgotinib in patients with rheumatoid arthritis, spanning data from three late-stage trials. An FDA decision on the drug is expected this year.

Covid-19 roundup: Mod­er­na read­ies to en­ter PhI­II in Ju­ly, As­traZeneca not far be­hind; EU ready to ne­go­ti­ate vac­cine ac­cess with $2.7B fund

Moderna may soon add another first to the Covid-19 vaccine race.

In March, the mRNA biotech was the first company to put a Covid-19 vaccine into humans. Next month, they may become the first company to put their vaccine into the large, late-stage trials that are needed to prove whether the vaccine is effective.

In an interview with JAMA editor Howard Bauchner, NIAID chief Anthony Fauci said that a 30,000-person, Phase III trial for Moderna’s vaccine could start in July. The news comes a week after Moderna began a Phase II study that will enroll several hundred people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.